🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. BCMA CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions

    phase 2 small molecule active

    1 trial

  2. BDC-1001, PERTUZUMAB

    Bolt Biotherapeutics

    HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER

    phase 2 small molecule active

    1 trial

  3. BEKINDA

    RedHill Biopharma

    Irritable Bowel Syndrome With Diarrhea

    phase 2 small molecule completed

    1 trial

  4. BENDAFOLIN 10 mg/ml Injektionslösung, Gemcitabin HEXAL® 40 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Benda-5 FU 50 mg/ml Injektionslösung, Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, AZD0901

    AstraZeneca AB

    Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  5. BENDAMUSTINE , CYTARABINE , VENETOCLAX , RITUXIMAB

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  6. BET-Inhibitor, Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 15 mg tablets, FEDRATINIB

    Bristol-Myers Squibb Australia Pty Ltd

    DIPSS-Intermediate or High Risk Myelofibrosis

    phase 2 small molecule active

    1 trial

  7. BEVACIZUMAB

    Pari Pharma GmbH

    Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection.

    phase 2 small molecule active

    1 trial

  8. BEVACIZUMAB, ATEZOLIZUMAB

    Pari Pharma GmbH

    liver transplanted patients with advanced hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  9. BEVACIZUMAB, DC-VACCINE_IRSTIRCCS, Lonsurf 20 mg/8.19 mg film-coated tablets, VEGZELMA 25 mg/mL concentrate for solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BEVACIZUMAB

    Istituto Gentili S.r.l.

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  10. BEVACIZUMAB, IRINOTECAN, FOLINIC ACID, Telisotuzumab adizutecan, FLUOROURACIL

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  11. BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, GEMCITABINE, NIVOLUMAB, PEMETREXED, PACLITAXEL, CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer, Interstitial Lung Disease

    phase 2 small molecule active

    1 trial

  12. BI 1815368, BI 1815368 Placebo, BI 1815368

    Boehringer Ingelheim

    Centre-involved diabetic macular edema

    phase 2 small molecule active

    1 trial

  13. BI 1819479, Placebo, Film-coated tablet, matching in size, weight, colour and shape to BI 1819479 (both unit strengths), BI 1819479

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  14. BI 1839100, Placebo matching in size, weight, colour and shape to tablets of BI 1839100

    Boehringer Ingelheim

    Progressive pulmonary fibrosis (PPF), Idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  15. BI 456906

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  16. BI 690517, Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat

    Boehringer Ingelheim

    chronic kidney disease

    phase 2 small molecule active

    1 trial

  17. BI 764524, Sham Injection Procedure

    Boehringer Ingelheim

    Diabetic retinopathy

    phase 2 small molecule active

    1 trial

  18. BI 907828, Ezabenlimab, BI 907828, BI 907828

    The George Institute

    Adult patients with locally advanced/metastatic solid tumors

    phase 2 small molecule active

    1 trial

  19. BINIMETINIB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB, IPILIMUMAB, ENCORAFENIB

    Pfizer Australia Pty Ltd

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 2 small molecule active

    1 trial

  20. BLEOPRIM 15 mg polvere per soluzione iniettabile, Carboplatino AHCL 10 mg/ml Concentrato per soluzione per infusione

    Istituto Gentili S.r.l.

    relapsing vulvar carcinoma already subjected to multiple treatments

    phase 2 small molecule active

    1 trial

  21. BLEOPRIM 15 mg polvere per soluzione iniettabile, Fluorouracil 50 mg/ml Solution for Injection or Infusion, LEDERFOLIN 25 mg Polvere per soluzione iniettabile per uso endovenoso, CAMPTO 20 mg/mL concentrate for solution for infusion, Oxaliplatin 5 mg/ml Concentrate for Solution for infusion

    Fondazione Telethon ETS

    Locally Advanced Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  22. BLEOPRIM 15 mg polvere per soluzione iniettabile, Fluorouracile Teva 250 mg/5 ml soluzione per infusione, CARBOPLATINO TEVA 10 mg/ml concentrato per soluzione per infusione, CETUXIMAB, PEMBROLIZUMAB, Cisplatino Teva Italia 0,5 mg/ml concentrato per soluzione per infusione

    Fondazione Telethon ETS

    CARCINOMA OF THE ORAL CAVITY AND OROPHARYNX

    phase 2 small molecule active

    1 trial

  23. BMB-101

    BRIGHT MINDS BIOSCIENCES INC.

    Absence Epilepsy

    phase 2 small molecule active

    1 trial

  24. BNT327 50 mg ml, BNT327 20 mg ml, IPILIMUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, BEVACIZUMAB, Ipilimumab

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources